Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

Lilly signs real-world digital diabetes deal with Livongo

Will work with the US consumer digital health firm on research collaboration

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

Alexa: find Novo Nordisk voice-activated diabetes tech

Hitlab challenge selects patient education firm Lighthouse for $50,000 funding

Lilly boosts its forthcoming diabetes digital health offering

Strikes diabetes deal with US software and analytics firm Rimidi

Sanofi reception

FDA approves Sanofi’s follow-on version of Lilly’s Humalog

French pharma firm hopes Admelog will make a significant commercial impact in 2018

- PMLiVE

Novo Nordisk gets FDA nod for once-weekly rival to Lilly’s Trulicity

GLP-1 agonist Ozempic approved in the US for type 2 diabetes

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

MSD outlines its AI needs in tech start-up programme

Continues its Velocity Health work with Wayra UK

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

- PMLiVE

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links